Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MILI ARORA

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1023249422
CMS profile
318134
Location
SACRAMENTO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$223.56

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $223.56 2

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
BeiGene USA, Inc. $133.96 1
Gilead Sciences, Inc. $89.60 1

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MILI ARORA

NPI 1023249422 · CMS profile ID 318134

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

SACRAMENTO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1023249422?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MILI ARORA, NPI 1023249422, CMS profile ID 318134. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1023249422?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). MILI ARORA, NPI 1023249422, CMS profile ID 318134. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1023249422?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
MILI ARORA, NPI 1023249422, CMS profile ID 318134, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1023249422?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $223.56 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
BeiGene USA, Inc. $133.9606/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051191345 CMS
Gilead Sciences, Inc. $89.6002/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025525891 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2020 $101.11 1
PY2021 $176.60 4
PY2022 $277.70 3
PY2023 $223.56 2
PY2024 $283.54 3
PY2025 $232.01 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $641,954.50 26
PY2024 Principal investigator $289,109.24 14
PY2023 Principal investigator $221,820.13 22
PY2022 Principal investigator $324,634.51 58
PY2021 Principal investigator $574,891.08 41
PY2020 Principal investigator $474,788.89 38
PY2019 Principal investigator $6,063.09 6

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

58 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Eli Lilly and Company $22.00 11/15/2022 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE No dispute reported 06/30/2026 917813433
Principal investigator 1 Seagen Inc. $11,504.00 11/09/2022 Covered Recipient Teaching Hospital
Uc Davis Medical Center
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917882839
Principal investigator 1 Seagen Inc. $51,837.00 11/09/2022 Covered Recipient Teaching Hospital
Uc Davis Medical Center
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917882845
Principal investigator 1 Eli Lilly and Company $1,394.00 10/26/2022 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
EMBER-3: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF LY3484356 VS INVESTIGATOR'S CHOICE OF ENDOCRINE THERAPY, IN PATIENTS WITH ESTROGEN RECEPTOR POSITIVE, HER2 NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER PREVIOUSLY TREATED WITH ENDOCRINE THERAPY No dispute reported 06/30/2026 917819625
Principal investigator 1 Seagen Inc. $441.00 09/21/2022 Covered Recipient Teaching Hospital
Uc Davis Medical Center
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917882671
Principal investigator 1 Eli Lilly and Company $31,382.00 09/19/2022 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
EMBER-3: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF LY3484356 VS INVESTIGATOR'S CHOICE OF ENDOCRINE THERAPY, IN PATIENTS WITH ESTROGEN RECEPTOR POSITIVE, HER2 NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER PREVIOUSLY TREATED WITH ENDOCRINE THERAPY No dispute reported 06/30/2026 917819407
Principal investigator 1 Seagen Inc. $1,600.00 09/14/2022 Covered Recipient Teaching Hospital
Uc Davis Medical Center
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917882573
Principal investigator 1 Seagen Inc. $4,078.62 08/03/2022 Covered Recipient Teaching Hospital
Uc Davis Medical Center
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917882607
Principal investigator 1 Seagen Inc. $307.44 08/03/2022 Covered Recipient Teaching Hospital
Uc Davis Medical Center
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917882613
Principal investigator 1 Seagen Inc. $4,078.62 08/03/2022 Covered Recipient Teaching Hospital
Uc Davis Medical Center
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917882619
Principal investigator 1 Seagen Inc. $307.44 08/03/2022 Covered Recipient Teaching Hospital
Uc Davis Medical Center
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917882625
Principal investigator 1 Seagen Inc. $441.00 08/03/2022 Covered Recipient Teaching Hospital
Uc Davis Medical Center
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917882630
Principal investigator 1 Seagen Inc. $2,503.62 08/03/2022 Covered Recipient Teaching Hospital
Uc Davis Medical Center
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917882635
Principal investigator 1 Seagen Inc. $2,503.62 08/03/2022 Covered Recipient Teaching Hospital
Uc Davis Medical Center
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917882642
Principal investigator 1 Seagen Inc. $441.00 08/03/2022 Covered Recipient Teaching Hospital
Uc Davis Medical Center
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917882647
Principal investigator 1 Seagen Inc. $441.00 08/03/2022 Covered Recipient Teaching Hospital
Uc Davis Medical Center
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917882655
Principal investigator 1 Seagen Inc. $441.00 08/03/2022 Covered Recipient Teaching Hospital
Uc Davis Medical Center
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917882661
Principal investigator 1 Seagen Inc. $2,503.62 08/03/2022 Covered Recipient Teaching Hospital
Uc Davis Medical Center
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917882665
Principal investigator 1 Seagen Inc. $307.44 04/06/2022 Covered Recipient Teaching Hospital
Uc Davis Medical Center
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917882369
Principal investigator 1 Seagen Inc. $441.00 04/06/2022 Covered Recipient Teaching Hospital
Uc Davis Medical Center
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917882375
Principal investigator 1 Seagen Inc. $2,503.62 04/06/2022 Covered Recipient Teaching Hospital
Uc Davis Medical Center
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917882383
Principal investigator 1 Seagen Inc. $307.44 04/06/2022 Covered Recipient Teaching Hospital
Uc Davis Medical Center
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917882471
Principal investigator 1 Seagen Inc. $2,503.62 04/06/2022 Covered Recipient Teaching Hospital
Uc Davis Medical Center
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917882477
Principal investigator 1 Seagen Inc. $441.00 04/06/2022 Covered Recipient Teaching Hospital
Uc Davis Medical Center
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917882483
Principal investigator 1 Seagen Inc. $2,503.62 04/06/2022 Covered Recipient Teaching Hospital
Uc Davis Medical Center
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917882489
Principal investigator 1 Seagen Inc. $307.44 04/06/2022 Covered Recipient Teaching Hospital
Uc Davis Medical Center
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917882495
Principal investigator 1 Seagen Inc. $307.44 04/06/2022 Covered Recipient Teaching Hospital
Uc Davis Medical Center
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917882501
Principal investigator 1 Seagen Inc. $307.44 04/06/2022 Covered Recipient Teaching Hospital
Uc Davis Medical Center
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917882507
Principal investigator 1 Seagen Inc. $307.44 04/06/2022 Covered Recipient Teaching Hospital
Uc Davis Medical Center
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917882513
Principal investigator 1 Seagen Inc. $8,941.67 04/04/2022 Covered Recipient Teaching Hospital
Uc Davis Medical Center
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917882519
Principal investigator 1 Seagen Inc. $35,960.00 03/14/2022 Covered Recipient Teaching Hospital
Uc Davis Medical Center
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917882549
Principal investigator 1 Seagen Inc. $307.44 02/09/2022 Covered Recipient Teaching Hospital
Uc Davis Medical Center
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917882331
Principal investigator 1 Seagen Inc. $441.00 02/09/2022 Covered Recipient Teaching Hospital
Uc Davis Medical Center
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917882339
Principal investigator 1 Seagen Inc. $2,503.62 02/09/2022 Covered Recipient Teaching Hospital
Uc Davis Medical Center
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917882345
Principal investigator 1 Seagen Inc. $4,078.62 02/09/2022 Covered Recipient Teaching Hospital
Uc Davis Medical Center
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917882349
Principal investigator 1 Seagen Inc. $3,173.94 02/09/2022 Covered Recipient Teaching Hospital
Uc Davis Medical Center
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917882355
Principal investigator 1 Seagen Inc. $5,869.14 02/09/2022 Covered Recipient Teaching Hospital
Uc Davis Medical Center
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917882363
Principal investigator 1 Seagen Inc. $441.00 02/09/2022 Covered Recipient Teaching Hospital
Uc Davis Medical Center
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917882389
Principal investigator 1 Seagen Inc. $4,078.62 02/09/2022 Covered Recipient Teaching Hospital
Uc Davis Medical Center
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917882395
Principal investigator 1 Seagen Inc. $2,503.62 02/09/2022 Covered Recipient Teaching Hospital
Uc Davis Medical Center
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917882402
Principal investigator 1 Seagen Inc. $2,503.62 02/09/2022 Covered Recipient Teaching Hospital
Uc Davis Medical Center
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917882407
Principal investigator 1 Seagen Inc. $307.44 02/09/2022 Covered Recipient Teaching Hospital
Uc Davis Medical Center
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917882413
Principal investigator 1 Seagen Inc. $2,503.62 02/09/2022 Covered Recipient Teaching Hospital
Uc Davis Medical Center
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917882419
Principal investigator 1 Seagen Inc. $307.44 02/09/2022 Covered Recipient Teaching Hospital
Uc Davis Medical Center
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917882425
Principal investigator 1 Seagen Inc. $441.00 02/09/2022 Covered Recipient Teaching Hospital
Uc Davis Medical Center
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917882431
Principal investigator 1 Seagen Inc. $2,503.62 02/09/2022 Covered Recipient Teaching Hospital
Uc Davis Medical Center
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917882437
Principal investigator 1 Seagen Inc. $2,503.62 02/09/2022 Covered Recipient Teaching Hospital
Uc Davis Medical Center
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917882443
Principal investigator 1 Seagen Inc. $2,503.62 02/09/2022 Covered Recipient Teaching Hospital
Uc Davis Medical Center
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917882449
Principal investigator 1 Seagen Inc. $5,869.14 02/09/2022 Covered Recipient Teaching Hospital
Uc Davis Medical Center
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917882455
Principal investigator 1 Seagen Inc. $2,503.62 02/09/2022 Covered Recipient Teaching Hospital
Uc Davis Medical Center
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917882459
Principal investigator 1 Seagen Inc. $4,078.62 02/09/2022 Covered Recipient Teaching Hospital
Uc Davis Medical Center
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 917882465
Principal investigator 1 Eli Lilly and Company $1,162.00 01/26/2022 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A MULTICENTER, RANDOMIZED, OPEN LABEL, PHASE 3 TRIAL COMPARING SELPERCATINIB TO PHYSICIANS CHOICE OF CABOZANTINIB OR VANDETANIB IN PATIENTS WITH PROGRESSIVE, ADVANCED, KINASE INHIBITOR NAIVE, RET MUTANT MEDULLARY THYROID CANCER (LIBRETTO 531) No dispute reported 06/30/2026 917821125
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $44,236.00 01/20/2022 Covered Recipient Teaching Hospital
Uc Davis Medical Center
Progressive Combinations- Metastatic ER HER2- Breast Cancer No dispute reported 06/30/2026 933199779
Principal investigator 1 Exelixis Inc. $3,500.00 01/12/2022 Covered Recipient Teaching Hospital
Uc Davis Medical Center
A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects with Radioiodine Refractory Differentiated Thyroid Cancer who have Progressed after Prior VEGFR-Targeted Therapy No dispute reported 06/30/2026 943766135
Principal investigator 1 Exelixis Inc. $2,920.00 01/12/2022 Covered Recipient Teaching Hospital
Uc Davis Medical Center
A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects with Radioiodine Refractory Differentiated Thyroid Cancer who have Progressed after Prior VEGFR-Targeted Therapy No dispute reported 06/30/2026 943766137
Principal investigator 1 Exelixis Inc. $4,050.00 01/12/2022 Covered Recipient Teaching Hospital
Uc Davis Medical Center
A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects with Radioiodine Refractory Differentiated Thyroid Cancer who have Progressed after Prior VEGFR-Targeted Therapy No dispute reported 06/30/2026 943766139
Principal investigator 1 Exelixis Inc. $650.00 01/12/2022 Covered Recipient Teaching Hospital
Uc Davis Medical Center
A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects with Radioiodine Refractory Differentiated Thyroid Cancer who have Progressed after Prior VEGFR-Targeted Therapy No dispute reported 06/30/2026 943766141
Principal investigator 1 Eli Lilly and Company $47,328.00 01/11/2022 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A MULTICENTER, RANDOMIZED, OPEN LABEL, PHASE 3 TRIAL COMPARING SELPERCATINIB TO PHYSICIANS CHOICE OF CABOZANTINIB OR VANDETANIB IN PATIENTS WITH PROGRESSIVE, ADVANCED, KINASE INHIBITOR NAIVE, RET MUTANT MEDULLARY THYROID CANCER (LIBRETTO 531) No dispute reported 06/30/2026 917813981